In another study, a short-term treatment with a weight-neutral dose of liraglutide could reverse the molecular pathophysiology of obesity-induced heart disease in mice through various mechanisms, among which a pivotal role is played by AMPK (38)
Diabetes Metab Syndr (2018) 12(3):46975
Retrieved from Teixeira, C
Another important difference lies in the interpretation of risk and benefit
Gene set enrichment analysis of ATMs from obese PAR2-G37I mice indicated a pronounced proinflammatory phenotype, characterized by upregulated signatures associated with interferon response, KRAS signaling, allograft rejection, and IL-2STAT5 signaling
Then tirzepatide arrived and raised the bar, adding a second receptor target and delivering results that made semaglutide look modest by comparison